

Sorrento Therapeutics, Inc.  
Form 8-K  
September 07, 2012

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

September 4, 2012

**Sorrento Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

Delaware

000-52228

33-0344842

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

6042 Cornerstone Ct. West, Suite B, San  
Diego, California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

858-210-3700

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form****Item 1.01 Entry into a Material Definitive Agreement.**

On September 4, 2012, the Board of Directors of Sorrento Therapeutics, Inc. (the Company) approved a form of indemnification agreement (the Indemnification Agreement) which the Company will offer to enter into with each of its directors and officers. The Indemnification Agreement, among other things, obligates the Company to indemnify a director or officer, to the fullest extent permitted by applicable law, for certain expenses, including attorneys' fees, judgments, penalties, fines and settlement amounts actually and reasonably incurred by them in any action or proceeding arising out of their services as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request, including liability arising out of negligence or active or passive misconduct by the officer or director.

The foregoing description of the Indemnification Agreement does not purport to be a complete description of the Indemnification Agreement, and is qualified in its entirety by reference to the full text of the Indemnification Agreement, which is filed as an exhibit to this Form 8-K and incorporated by reference in this Item 1.01.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

At the Annual Meeting of Stockholders of the Company held on September 6, 2012, the Company's stockholders considered two proposals.

**Proposal 1** Election of seven members to the Company's Board of Directors to serve until the 2013 Annual Meeting of Stockholders.

The results of the voting for Proposal 1 were as follows:

<b>Nominee</b>	<b>Shares Voted For</b>	<b>Voting Authority Withheld</b>	<b>Broker Non-Votes</b>
Henry Ji, Ph. D.	192,401,855.0	95,113,221.1	693,661.0
Kim D. Janda, Ph. D.	192,101,855.0	95,413,221.1	693,661.0
M. Scott Salka	192,101,855.0	95,413,221.1	693,661.0
Richard Vincent	176,781,284.0		
Ernst-Gunter Afting, Ph.D., M.D.	176,781,284.0		
David Webb, Ph.D.	176,781,284.0		
Cam Gallagher	176,781,284.0		
Glenn L. Halpryn	110,053,551.1	680,241.0	693,661.0
Jane Hsiao, Ph. D.	110,194,673.9	539,118.2	693,661.0
Curtis Lockshin, Ph. D.	110,194,673.9	539,118.2	693,661.0
Diane D-S. Tang-Liu, Ph. D.	110,194,673.9	539,118.2	693,661.0

Edgar Filing: Sorrento Therapeutics, Inc. - Form 8-K

Based on the votes set forth above, the following nominees were duly elected: Henry Ji, Ph.D., Kim D. Janda, Ph.D., M. Scott Salka, Richard Vincent, Ernst-Gunter Afting, Ph.D., M.D., David Webb, Ph.D., and Cam Gallagher.

**Proposal 2** Ratification of the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accountants for the fiscal year ending December 31, 2012.

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
287,619,551.0	1,450.0	587,736.1	

Based on the votes set forth above, Proposal 2 was approved.  
No other matters were considered or voted upon at the meeting.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit #</b>	<b>Description</b>
10.1	Form of Indemnification Agreement dated September 4, 2012

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Sorrento Therapeutics, Inc.

*September 6, 2012*

By: *Henry Ji*

---

*Name: Henry Ji*

*Title: Interim CEO and Chief Scientific Officer*

---

**Top of the Form**

Exhibit Index

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
10.1	Form of Indemnification Agreement